Glycation Isotopic Labeling with 13C-Reducing Sugars for Quantitative Analysis of Glycated Proteins in Human Plasma*

Non-enzymatic glycation of proteins is a post-translational modification produced by a reaction between reducing sugars and amino groups located in lysine and arginine residues or in the N-terminal position. This modification plays a relevant role in medicine and food industry. In the clinical field, this undesired role is directly linked to blood glucose concentration and therefore to pathological conditions derived from hyperglycemia (>11 mm glucose) such as diabetes mellitus or renal failure. An approach for qualitative and quantitative analysis of glycated proteins is here proposed to achieve the three information levels for their complete characterization. These are: 1) identification of glycated proteins, 2) elucidation of sugar attachment sites, and 3) quantitative analysis to compare glycemic states. Qualitative analysis was carried out by tandem mass spectrometry after endoproteinase Glu-C digestion and boronate affinity chromatography for isolation of glycated peptides. For this purpose, two MS operational modes were used: higher energy collisional dissociation-MS2 and CID-MS3 by neutral loss scan monitoring of two selective neutral losses (162.05 and 84.04 Da for the glucose cleavage and an intermediate rearrangement of the glucose moiety). On the other hand, quantitative analysis was based on labeling of proteins with [13C6]glucose incubation to evaluate the native glycated proteins labeled with [12C6]glucose. As glycation is chemoselective, it is exclusively occurring in potential targets for in vivo modifications. This approach, named glycation isotopic labeling, enabled differentiation of glycated peptides labeled with both isotopic forms resulting from enzymatic digestion by mass spectrometry (6-Da mass shift/glycation site). The strategy was then applied to a reference plasma sample, revealing the detection of 50 glycated proteins and 161 sugar attachment positions with identification of preferential glycation sites for each protein. A predictive approach was also tested to detect potential glycation sites under high glucose concentration.

[1]  P. Flatt,et al.  Glycation of insulin results in reduced biological activity in mice , 1997, Acta Diabetologica.

[2]  R. Appel,et al.  On the benefits of acquiring peptide fragment ions at high measured mass accuracy , 2008, Journal of the American Society for Mass Spectrometry.

[3]  K. Miedema Towards worldwide standardisation of HbA1c determination , 2004, Diabetologia.

[4]  L. Maillard,et al.  Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .

[5]  Chris F. Taylor,et al.  A common open representation of mass spectrometry data and its application to proteomics research , 2004, Nature Biotechnology.

[6]  Richard D. Smith,et al.  Analysis of non-enzymatically glycated peptides: neutral-loss-triggered MS(3) versus multi-stage activation tandem mass spectrometry. , 2008, Rapid communications in mass spectrometry : RCM.

[7]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[8]  P. Hoffmann,et al.  Fragmentation behavior of glycated peptides derived from D-glucose, D-fructose and D-ribose in tandem mass spectrometry. , 2006, Journal of mass spectrometry : JMS.

[9]  R. Flückiger,et al.  Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. , 1986, The Journal of biological chemistry.

[10]  F. Pattou,et al.  Glucotoxicity inhibits late steps of insulin exocytosis. , 2007, Endocrinology.

[11]  R. Campbell,et al.  Site specificity of glycation of horse liver alcohol dehydrogenase in vitro. , 1993, European journal of biochemistry.

[12]  C. Calvo,et al.  Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. , 1988, Biochemical and biophysical research communications.

[13]  H. Chandalia,et al.  Glycated Hemoglobin , 2020 .

[14]  D. Goodlett,et al.  Increasing information from shotgun proteomic data by accounting for misassigned precursor ion masses , 2008, Proteomics.

[15]  J. Baynes,et al.  The role of AGEs in aging: causation or correlation , 2001, Experimental Gerontology.

[16]  Richard D. Smith,et al.  Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. , 2008, Journal of proteome research.

[17]  G. Gill,et al.  Protein glycosylation in diabetes mellitus: biochemical and clinical considerations , 2000 .

[18]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[19]  I. Jerić,et al.  Tracing glycoprotein structures: electrospray ionization tandem mass spectrometric analysis of sugar-peptide adducts. , 2002, Journal of mass spectrometry : JMS.

[20]  M. Mann,et al.  Higher-energy C-trap dissociation for peptide modification analysis , 2007, Nature Methods.

[21]  R. Kalyani,et al.  Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. , 2006, JAMA.

[22]  A. Hipkiss,et al.  Accumulation of altered proteins and ageing: Causes and effects , 2006, Experimental Gerontology.

[23]  T. Metz,et al.  Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. , 2003, Journal of proteome research.

[24]  J. Baynes,et al.  The Amadori product on protein: structure and reactions. , 1989, Progress in clinical and biological research.

[25]  M. Brownlee Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[26]  H. Kaneto,et al.  Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. , 2008, Endocrine journal.

[27]  J. Cipollo,et al.  A glycomics platform for the analysis of permethylated oligosaccharide alditols , 2007, Journal of the American Society for Mass Spectrometry.

[28]  Lukas N. Mueller,et al.  SuperHirn – a novel tool for high resolution LC‐MS‐based peptide/protein profiling , 2007, Proteomics.

[29]  C. Calvo,et al.  Association in Vivo of Glycated Apolipoprotein A-I with High Density Lipoproteins , 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[30]  Qibin Zhang,et al.  A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. , 2009, Journal of proteome research.

[31]  D. Leroith Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. , 2002, The American journal of medicine.

[32]  K. Baynes,et al.  Artefactually low glycated haemoglobin is a potential pitfall in diabetes management: consider congenital haemolytic anaemias , 2001 .

[33]  S. Brunak,et al.  Analysis and prediction of mammalian protein glycation. , 2006, Glycobiology.

[34]  A. Ohnishi,et al.  Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[35]  A. Cerami,et al.  Protein glycation, diabetes, and aging. , 2001, Recent progress in hormone research.

[36]  J. Reusch,et al.  Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? , 2003, The Journal of clinical investigation.

[37]  C. Calvo,et al.  Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. , 1988, Diabete & metabolisme.

[38]  A. Goldfine,et al.  Molecular basis for a link between complement and the vascular complications of diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Michael Brownlee,et al.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. , 2006, JAMA.

[40]  Jean-Charles Sanchez,et al.  Glucotoxicity and pancreatic proteomics. , 2009, Journal of proteomics.

[41]  J. Wojcicki,et al.  Validation of Hemoglobin Glycation Models Using Glycemia Monitoring In Vivo and Culturing of Erythrocytes In Vitro , 2008, Annals of Biomedical Engineering.

[42]  M. Mann,et al.  Precision proteomics: The case for high resolution and high mass accuracy , 2008, Proceedings of the National Academy of Sciences.

[43]  M. Mann,et al.  Global and site-specific quantitative phosphoproteomics: principles and applications. , 2009, Annual review of pharmacology and toxicology.